Peer-influenced content. Sources you trust. No registration required. This is HCN.
Journal of Clinical Oncology
Despite aggressive therapy, the 5-year survival rate for patients with metastatic or recurrent rhabdomyosarcoma – the most common soft tissue sarcoma of childhood – remains poor, and beyond PAX-FOX01 fusion status, no genomic markers are available for risk stratification. This international consortium study was designed to determine the incidence of driver mutations and their association with clinical outcome.
Internal Medicine July 6th 2021